{reportSlug=global-acute-myeloid-leukemia-therapeutics-market, reportId=980, mktKeyword=Acute Myeloid Leukemia Therapeutics, cagr=0.00, publishDate=Jul 2023, priceOption2=7500, reportTitle=Acute Myeloid Leukemia Therapeutics Comprehensive Study by Type (Pipeline Drugs, Chemotherapy Drugs, Chemotherapy Regimens), Application (Hospitals, Clinics, Home Care), Drug Type (Bosutinib, Vidaza, Omapro, Quizartinib, Dacogen, Clolar, Gleevac, Sprycel, Others), Disease Type (Undifferentiated Acute Myeloblastic, Acute Myeloblastic Leukemia with Minimal Maturation, Acute Myeloblastic Leukemia with Maturation, Acute Promyelocytic Leukemia (APL), Acute Myelomonocytic Leukemia, Acute Myelomonocytic Leukemia with Eosinophilia, Acute Monocytic Leukemia, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia) Players and Region - Global Market Outlook to 2028, baseYr=2022, totalTableFig=198, priceOption1=3750, forecastYr=2028, noOfPages=247, reportKey=916, breadcrum=Global Acute Myeloid Leukemia Therapeutics}
We do not share your information with anyone. However, we may send you
emails based on your report interest from time to time. You may contact
us at any time to opt-out.
Select User Access Type
Key Highlights of Report
Jul 2023
247 Pages
70 Tables
Base Year: 2022Coverage: 15+ Companies; 18
Countries